COVID-19 may become nanomedicine's finest hour yet

Nat Nanotechnol. 2021 Apr;16(4):362-364. doi: 10.1038/s41565-021-00901-8.

Authors

Steffi Friedrichs¹, Diana M Bowman²

Affiliations

¹ AcumenIST, Brussels, Belgium. steffi@acumenist.com.
² Sandra Day O'Connor College of Law, Arizona State University, Phoenix, AZ, USA.

PMID: 33854220
DOI: 10.1038/s41565-021-00901-8

No abstract available

MeSH terms

2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
COVID-19 / epidemiology
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / pharmacology*
Drug Approval
Drug Delivery Systems / methods
Drug Development / methods
Drug Development / trends
Global Health
Humans
Nanomedicine / methods*
Nanomedicine / trends
Nanotechnology / methods
Nanotechnology / trends
Pandemics* / prevention & control
RNA, Messenger / genetics
SARS-CoV-2* / genetics
SARS-CoV-2* / immunology
Time Factors
Vaccines, Synthetic / pharmacology
mRNA Vaccines

Substances

COVID-19 Vaccines
RNA, Messenger
Vaccines, Synthetic
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine